Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

San Francisco, California 94118


The National Heart, Lung, and Blood Institute (NHLBI) has established guidelines for treating people with asthma. This study will evaluate the effectiveness of a distance learning program that aims to educate doctors on these guidelines, specifically the use of inhaled corticosteroids to treat asthma in pediatric patients.

Study summary:

Asthma is a long-term lung disease that affects more than 22 million people in the United States. Symptoms include wheezing, chest tightness, shortness of breath, and coughing. Inhaled corticosteroids are a common medication used to treat asthma. NHLBI has established guidelines for doctors to reference when treating people with asthma. Study researchers previously evaluated a distance learning program aimed to educate doctors on the NHLBI guidelines and to improve pediatrician adherence to the guideline recommendations for the use of daily inhaled corticosteroids for persistent asthma in pediatric patients. This pilot study will evaluate a new version of the distance learning program. By using a distance learning program rather than a traditional face-to-face educational program, participants will be able to complete the program on their own schedule, and this flexibility may result in increased interest in the program. The purpose of this study is to evaluate the effectiveness of the new distance learning program on changing pediatricians' behavior, attitudes, and knowledge regarding the NHLBI guidelines for the use of inhaled corticosteroids to treat pediatric patients with asthma. This study will enroll pediatricians. Participants will be randomly assigned to either the distance learning group or a control group. At baseline, all participants will complete questionnaires. Participants in the control group will not take part in any of the educational activities. Participants in the distance learning group will take part in a 1-hour Webinar, or teleconference, that will provide an orientation to the program and discuss the importance of the NHLBI guidelines. At any time between the first Webinar and a 6-week follow-up Webinar, participants will log into the study Web site and complete a training module that aims to educate participants on common barriers to prescribing daily inhaled corticosteroids. As an alternative to the Web site, participants may choose to view the training module on a CD-ROM. Six weeks after the first Webinar, participants will take part in a follow-up Webinar. At this time, study researchers will answer participants' questions and provide a program review. The Web site and study materials will remain available to participants in the distance learning group for 6 months after the follow-up Webinar; a list serve will also be made available to participants. At 1 and 6 months after the follow-up Webinar, all participants will complete questionnaires.


Inclusion Criteria: - Board-eligible pediatricians involved in direct primary care for children - Has access to a Windows or Macintosh computer with either a CD-ROM drive or Internet access - Has access to a telephone for teleconference calls - Willing to take part in the DALI educational seminar if assigned to the intervention group

Study is Available At:

Original ID:




Secondary ID:


Study Acronym:


Brief Title:

Evaluating a Distance Learning Asthma Education Program for Pediatricians (The DALI Study)

Official Title:

Distributed Asthma Learning Initiative

Overall Status:


Study Phase:




Minimum Age:

18 Years

Maximum Age:


Quick Facts

Healthy Volunteers
Oversight Has DMC
Study Is FDA Regulated
Study Is Section 801
Has Expanded Access

Study Source:

University of California, San Francisco

Oversight Authority:

United States: Federal Government

Reasons Why Stopped:

Study Type:


Study Design:

Allocation: Randomized, Endpoint Classification:

Number of Arms:


Number of Groups:


Total Enrollment:


Enrollment Type:


Overall Contact Information

Official Name:Michael D. Cabana, MD, MPH
Principal Investigator
University of California, San Francisco

Study Dates

Start Date:February 2007
Completion Date:March 2008
Completion Type:Actual
Primary Completion Date:March 2008
Primary Completion Type:Actual
Verification Date:March 2013
Last Changed Date:March 7, 2013
First Received Date:December 29, 2008

Study Outcomes

Outcome Type:Primary Outcome
Measure:Learner satisfaction
Time Frame:Measured at Months 1 and 6
Safety Issues:False
Outcome Type:Primary Outcome
Measure:Change in physician asthma knowledge, attitudes, and treatment behavior
Time Frame:Measured at Months 1 and 6
Safety Issues:False

Study Interventions

Intervention Type:Behavioral
Name:Distributed Asthma Learning Initiative (DALI) dist
Description:Participants will take part in two Webinar teleconferences, have access to an interactive Web site, and receive a CD-ROM of study materials and a toolkit.
Arm Name:1

Study Arms

Study Arm Type:No Intervention
Arm Name:2
Description:Participants in the control group will not receive any study materials or take part in any study activities.
Study Arm Type:Experimental
Arm Name:1
Description:Participants will take part in a distance learning group.

Study Agencies

Agency Class:Other
Agency Type:Lead Sponsor
Agency Name:University of California, San Francisco
Agency Class:NIH
Agency Type:Collaborator
Agency Name:National Heart, Lung, and Blood Institute (NHLBI)

Sample and Retention Information

There are no available Sample and Retention Information

Study References

There are no available Study References

Data Source: ClinicalTrials.gov

Date Processed: January 21, 2020

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

This study is not currently recruiting Study Participants. The form below is not enabled.